FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3178223390> ?p ?o ?g. }

• W3178223390 abstract "Objective: The present study aims to establish recommendations agreed by Spanish multiple sclerosis (MS) experts on how, when and what variables should be measured to assess disease modifying treatments (DMTs) response. Background: MS presents great variability and heterogeneity, making its prognosis and treatment response uncertain. The establishment of unified therapeutic response criteria can optimize DMTs results. Design/Methods: 25 expert neurologists in MS were involved in the design of an online RAND/UCLA questionnaire (divided in 9 blocks and 54 questions) to obtain a national consensus in the evaluation of DMTs suboptimal response. Each block contained different number of questions and each question could be answered according to a 4-point Likert scale (strongly disagree, disagree, agree or strongly agree). Consensus was considered when the sum of the “Strongly Agree” and “Agree” or the sum of the “Strongly disagree” and “Disagree” responses was ≥66.6%. Results: 151 MS experts from 41 Spanish provinces, mostly working in tertiary hospitals (67.2%) participated in this national survey, of whom 64.9% (n=98) and 35.1% (n=53) of neurologists totally and partially completed the questionnaire, respectively. The proportion of agreement for each block was: 1) Therapeutic response: 77.8%, 2) Relapses: 100.0%, 3) Magnetic resonance imaging: 73.3%, 4) Biomarkers: 75.0%, 5) Disability progression: 100.0%, 6) Brain volume loss: 66.7%, 7) Neuropsychological aspects: 100.0%, 8) DMTs switch due to lack of response: 57.1%, 9) Clinical practice: 100.0%. The more challenging aspect to discuss was the DMTs switch due to lack of response; no agreement was obtained in this block of questions. Most of the experts (82.7%) state that the suggested practices are implementable in routine clinical practice. Conclusions: Consensus (≥66.6% agreement) was obtained in 8 out of the 9 blocks of the recommendations to assess DMTs response. Disclosure: Dr. Rio has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck, Novartis, Roche, Sanofi, Biogen, and Teva. Dr. Pena Martinez has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Congress travel support and/or speaker fees and/or advisory board fees from Novartis, Biogen, Sanofi, Teva, Roche and Merck. Dr. Pena Martinez has received research support from Sanofi. Dr. Brieva Ruiz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Cellgene (advisory board). Dr. Oreja Guevara has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Honoraria for speaking and/or consultancy from Biogen, Sanofi- Genzyme, Merck, Roche, Teva, and Novartis. Dr. Costa-Frossard has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dra. Costa-Frossard has received speaking honoraria and travel expenses for scientific meetings in the past 3 years whit Biogen Idec, Merchk Serono, Gensyme, Novartis, Sanofi-Avents, Teva, Roche, Celgene, Actelion and Almirall. Dr. Costa-Frossard has received research support from Dra. Costa-Frossard has been a steering committee member of clinical trials or partipated in advisory boards of clinical trials in the past 3 years whit Biogen Idec, Merchk Serono, Gensyme, Novartis, Sanofi-Avents, Teva, Roche, Celgene, Actelion and Almir. Dr. Rodriguez Antiguedad has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with MERCK, BIOGEN IDEC, ROCHE, GENZYME, TEVA, MYLAND, CELGENE. Dr. Garcia Dominguez has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis, Sanofi, Biogen, Almirall, Roche, and Merck. Dr. Baz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with She has received personal compensation for activities with Novartis. Dr. Baz has received research support from Novartis.Dr. MORENO JIMENEZ has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with MJM has received personal compensation for activities with Novartis Pharma AG as an employee. Dr. MORENO JIMENEZ has received research support from MJM has received personal compensation for activities with Novartis Pharma AG as an employee. Dr. Hernandez has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis.Dr. Arroyo Gonzalez has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis, Roche, Teva, Biogen, Genzyme, Merck, and Celgene." @default.
• W3178223390 created "2021-07-19" @default.
• W3178223390 creator A5012280776 @default.
• W3178223390 creator A5017594583 @default.
• W3178223390 creator A5018280433 @default.
• W3178223390 creator A5045128052 @default.
• W3178223390 creator A5066855738 @default.
• W3178223390 creator A5066995854 @default.
• W3178223390 creator A5070612898 @default.
• W3178223390 creator A5075510658 @default.
• W3178223390 creator A5077701566 @default.
• W3178223390 creator A5079962370 @default.
• W3178223390 creator A5088301395 @default.
• W3178223390 date "2020-04-14" @default.
• W3178223390 modified "2023-09-23" @default.
• W3178223390 title "Assessment and Follow-up of the Response to Disease Modifying Treatments in Multiple Sclerosis: Spanish Expert Consensus (1786)" @default.
• W3178223390 hasPublicationYear "2020" @default.
• W3178223390 type Work @default.
• W3178223390 sameAs 3178223390 @default.
• W3178223390 citedByCount "0" @default.
• W3178223390 crossrefType "journal-article" @default.
• W3178223390 hasAuthorship W3178223390A5012280776 @default.
• W3178223390 hasAuthorship W3178223390A5017594583 @default.
• W3178223390 hasAuthorship W3178223390A5018280433 @default.
• W3178223390 hasAuthorship W3178223390A5045128052 @default.
• W3178223390 hasAuthorship W3178223390A5066855738 @default.
• W3178223390 hasAuthorship W3178223390A5066995854 @default.
• W3178223390 hasAuthorship W3178223390A5070612898 @default.
• W3178223390 hasAuthorship W3178223390A5075510658 @default.
• W3178223390 hasAuthorship W3178223390A5077701566 @default.
• W3178223390 hasAuthorship W3178223390A5079962370 @default.
• W3178223390 hasAuthorship W3178223390A5088301395 @default.
• W3178223390 hasConcept C105776082 @default.
• W3178223390 hasConcept C118552586 @default.
• W3178223390 hasConcept C138496976 @default.
• W3178223390 hasConcept C14216870 @default.
• W3178223390 hasConcept C15744967 @default.
• W3178223390 hasConcept C169900460 @default.
• W3178223390 hasConcept C2776036978 @default.
• W3178223390 hasConcept C2777703276 @default.
• W3178223390 hasConcept C2780640218 @default.
• W3178223390 hasConcept C2780892749 @default.
• W3178223390 hasConcept C512399662 @default.
• W3178223390 hasConcept C71924100 @default.
• W3178223390 hasConceptScore W3178223390C105776082 @default.
• W3178223390 hasConceptScore W3178223390C118552586 @default.
• W3178223390 hasConceptScore W3178223390C138496976 @default.
• W3178223390 hasConceptScore W3178223390C14216870 @default.
• W3178223390 hasConceptScore W3178223390C15744967 @default.
• W3178223390 hasConceptScore W3178223390C169900460 @default.
• W3178223390 hasConceptScore W3178223390C2776036978 @default.
• W3178223390 hasConceptScore W3178223390C2777703276 @default.
• W3178223390 hasConceptScore W3178223390C2780640218 @default.
• W3178223390 hasConceptScore W3178223390C2780892749 @default.
• W3178223390 hasConceptScore W3178223390C512399662 @default.
• W3178223390 hasConceptScore W3178223390C71924100 @default.
• W3178223390 hasLocation W31782233901 @default.
• W3178223390 hasOpenAccess W3178223390 @default.
• W3178223390 hasPrimaryLocation W31782233901 @default.
• W3178223390 hasRelatedWork W2799729405 @default.
• W3178223390 hasRelatedWork W2807519117 @default.
• W3178223390 hasRelatedWork W2809796400 @default.
• W3178223390 hasRelatedWork W2823358944 @default.
• W3178223390 hasRelatedWork W2885192722 @default.
• W3178223390 hasRelatedWork W2887617285 @default.
• W3178223390 hasRelatedWork W2890304873 @default.
• W3178223390 hasRelatedWork W2951843712 @default.
• W3178223390 hasRelatedWork W2971207021 @default.
• W3178223390 hasRelatedWork W3043124915 @default.
• W3178223390 hasRelatedWork W3095614647 @default.
• W3178223390 hasRelatedWork W3095735295 @default.
• W3178223390 hasRelatedWork W3098560048 @default.
• W3178223390 hasRelatedWork W3111961654 @default.
• W3178223390 hasRelatedWork W3131226976 @default.
• W3178223390 hasRelatedWork W3187114413 @default.
• W3178223390 hasRelatedWork W3193882913 @default.
• W3178223390 hasRelatedWork W3204438537 @default.
• W3178223390 hasRelatedWork W3210868170 @default.
• W3178223390 hasRelatedWork W3213212376 @default.
• W3178223390 hasVolume "94" @default.
• W3178223390 isParatext "false" @default.
• W3178223390 isRetracted "false" @default.
• W3178223390 magId "3178223390" @default.
• W3178223390 workType "article" @default.